Endocrine Toxicities of Antineoplastic Therapy

Puliani, Giulia; Appetecchia, Marialuisa

doi:10.3390/cancers13020294

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Minor imbalances were noted in a KEYNOTE-426 trial for pembrolizumab plus axitinib (0.7% vs. 0.2% for sunitinib) [ 34 ], and a CLEAR trial for lenvatinib plus pembrolizumab (1.1% vs. 0% for sunitinib) [ 35 ]. Our real-world data found a median latency of three months for the combination regimen, with remarkable high rates of discontinuation and dechallenge, thus suggesting the importance of implementing dedicated guidelines and screening protocols (ACTH test) through a close collaboration among pharmacologists, internists, oncologists and endocrinologists [ 4 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Raschi

Fusaroli

Giunchi

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: We described clinical features of adrenal insufficiency (AI) reported with tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR) in the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Reports of AI recorded in FAERS (January 2004–March 2022) were identified through the high-level term “adrenal cortical hypofunctions”. Demographic and clinical features were inspected, and disproportionality signals were detected through the Reporting Odds Ratio (ROR) and Information Component (IC) with relevant 95% confidence/credibility interval (CI), using different comparators and adjusting the ROR for co-reported corticosteroids and immune checkpoint inhibitors (ICIs). Results: Out of 147,153 reports with VEGFR-TKIs, 314 cases of AI were retained, mostly of which were serious (97.1%; hospitalization recorded in 44.9%). In a combination regimen with ICIs (43% of cases), VEGFR-TKIs were discontinued in 52.2% of the cases (26% as monotherapy). The median time to onset was 72 days (IQR = 14–201; calculated for 189 cases). A robust disproportionality signal emerged, also in comparison with other anticancer drugs (ROR = 2.71, 95%CI = 2.42–3.04; IC = 0.25, 95%CI = 0.07–0.39). Cabozantinib, sunitinib and axitinib generated robust disproportionality even after ROR adjustment. Conclusions: We call pharmacologists, internists, oncologists and endocrinologists to raise awareness of serious AI with VEGFR-TKIs, and to develop dedicated guidelines, especially for combination regimens with immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System

Raschi

Fusaroli

Giunchi

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The scrips are not delivered for longer periods which again creates liquidity problem. SEBI is trying to frame rules where this malpractice will be curtailed [3] . 18.…”

Section: Excessive Speculationmentioning

confidence: 99%

A study of problems of stock exchange in India

Singla¹

2021

Int. J. Res. Marketing Manage. Sales

View full text Add to dashboard Cite

In this paper we will sought out the problems of stock exchange in India and adjust the tone & tune with the market rhythm, external and internal environment. There are so many rules, regulations, standards, procedures and functions formed improved by regulatory authorities for the removal of short comings of stock trading system in order to raising investment with transparency among invertors and traders.

show abstract